HCWB (HCW Biologics) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


HCWB HCW Biologics Inc HCWB
39 GF Score
Price $1.15
GF Value $7.29
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is HCW Biologics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

HCW Biologics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

HCWB vs MTVA, INTI, HOOK: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, HCW Biologics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HCW Biologics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HCW Biologics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where HCW Biologics's Margin of Safety % (DCF Earnings Based) falls into.


HCWB
39GF Score
HCW Biologics Inc HCWB
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HCW Biologics (HCWB) Overvalued in 2026?

Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued. The current stock price of $1.15 is trading 84.2% below its estimated GF Value™ of $7.29. GuruFocus considers HCW Biologics to be Possible Value Trap.

Key valuation signals for HCWB:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $7.29 vs. price of $1.15 (84.2% below fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HCW Biologics Business Description

Address 2929 N. Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score

Get the complete analysis for HCWB

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price
$7.29
GF Value